Monarch Technologies receives CHF 40,000 from Venture Kick to accelerate validation toward clinical translation
16.06.2026
Monarch Technologies receives CHF 40,000 from Venture Kick to advance its adaptive drug delivery platform for locoregional cancer therapies. By dynamically overcoming biological barriers during treatment, the technology enhances drug delivery directly to tumors, aiming to improve therapeutic efficacy while reducing side effects for cancer patients.
 Lorenz Kehrbein, Lukas Hertle, Shen Ning
|
 |
What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you?
The first real signal came when we shared our early results with interventional radiologists and oncologists around the world. Instead of just discussing the science, they immediately started asking how and when they could use the technology in clinical practice.
That was a turning point. Their enthusiasm showed us we were addressing a real clinical need, not just developing an interesting technology. It also reinforced our focus on building a solution that fits seamlessly into existing clinical workflows.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Monarch Technologies is developing a modular drug delivery platform designed to improve the efficacy and safety of locoregional cancer therapies. Unlike conventional approaches, our technology adapts throughout treatment to overcome biological barriers and enhance drug delivery directly to tumors.
When we entered Venture Kick, we had already demonstrated promising preclinical proof of concept, with improved drug accumulation and anti-tumor efficacy. However, we were still refining our commercialization strategy, identifying the best initial clinical indication, and validating the market opportunity.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Before Venture Kick, our focus was primarily on the technology itself. The program pushed us to engage much more deeply with clinicians, healthcare stakeholders, and industry experts.
Those conversations helped us better understand clinical needs, refine our target indication, and prioritize features that support adoption. They also led to valuable translational research collaborations that are helping us validate the technology more quickly and effectively.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding will help us further de-risk both the technology and the business case. We’ll use it to conduct targeted preclinical studies, strengthen our regulatory strategy, and generate additional evidence supporting the platform.
At the same time, we’ll continue engaging clinicians, healthcare providers, and industry partners to validate our market assumptions and build strategic collaborations that can accelerate development and future commercialization.
The first real signal came when we shared our early results with interventional radiologists and oncologists around the world. Instead of just discussing the science, they immediately started asking how and when they could use the technology in clinical practice.
That was a turning point. Their enthusiasm showed us we were addressing a real clinical need, not just developing an interesting technology. It also reinforced our focus on building a solution that fits seamlessly into existing clinical workflows.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Monarch Technologies is developing a modular drug delivery platform designed to improve the efficacy and safety of locoregional cancer therapies. Unlike conventional approaches, our technology adapts throughout treatment to overcome biological barriers and enhance drug delivery directly to tumors.
When we entered Venture Kick, we had already demonstrated promising preclinical proof of concept, with improved drug accumulation and anti-tumor efficacy. However, we were still refining our commercialization strategy, identifying the best initial clinical indication, and validating the market opportunity.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Before Venture Kick, our focus was primarily on the technology itself. The program pushed us to engage much more deeply with clinicians, healthcare stakeholders, and industry experts.
Those conversations helped us better understand clinical needs, refine our target indication, and prioritize features that support adoption. They also led to valuable translational research collaborations that are helping us validate the technology more quickly and effectively.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding will help us further de-risk both the technology and the business case. We’ll use it to conduct targeted preclinical studies, strengthen our regulatory strategy, and generate additional evidence supporting the platform.
At the same time, we’ll continue engaging clinicians, healthcare providers, and industry partners to validate our market assumptions and build strategic collaborations that can accelerate development and future commercialization.